US 11,718,652 B2
Human neuregulin-1 (NRG-1) recombinant fusion protein compositions and methods of use thereof
John Li, Reston, VA (US); Shengwei Li, Chengdu (CN); Dixiang Luo, Chengdu (CN); Yiran Wu, Chengdu (CN); Ming Zhou, Shandong (CN); Yang Wang, Chengdu (CN); Xiaolei Zhuang, North Potomac, MD (US); Liang Hua, Zigong (CN); and Pengyi Luo, Chengdu (CN)
Assigned to Salubris Biotherapeutics, Inc., Gaithersburg, MD (US); and Salubris (Chengdu) Biotech Co., Ltd.
Filed by Salubris Biotherapeutics, Inc., Gaithersburg, MD (US); and Salubris (Chengdu) Biotech Co., Ltd., Chengdu (CN)
Filed on May 21, 2021, as Appl. No. 17/327,494.
Application 17/327,494 is a continuation of application No. 16/381,206, filed on Apr. 11, 2019, granted, now 11,046,741.
Claims priority of provisional application 62/656,246, filed on Apr. 11, 2018.
Prior Publication US 2021/0347841 A1, Nov. 11, 2021
This patent is subject to a terminal disclaimer.
Int. Cl. C07K 14/475 (2006.01); C12N 15/90 (2006.01); A61K 38/00 (2006.01)
CPC C07K 14/4756 (2013.01) [C12N 15/907 (2013.01); A61K 38/00 (2013.01); C07K 2319/00 (2013.01)] 35 Claims
OG exemplary drawing
 
1. A method of treating a cardiovascular disease or condition in a subject, comprising administering between 0.1 mcg/kg and 5 mg/kg of a recombinant fusion protein comprising a fragment of the cardioprotective protein neuregulin-1 (NRG-1) fused to a monospecific ErbB3 (HER3) monoclonal antibody (mAb).